Fleming Indications/Uses

Fleming is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The β-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other β-lactam antibiotics.
Fleming oral presentations are indicated for short-term treatment of bacterial infections at the following sites: Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media.
Lower Respiratory Tract Infections in particular acute exacerbations of chronic bronchitis (especially if considered severe), bronchopneumonia. These infections are often caused by Streptococcus pneumoniae, Haemophilus influenzae* and Moraxella catarrhalis*.
Genito-urinary Tract and Abdominal Infections in particular cystitis (especially when recurrent or complicated - excluding prostatitis). These infections are often caused by Enterobacteriaceae* (mainly Escherichia coli*), Staphylococcus saprophyticus, Enterococcus species.
Skin and Soft Tissue Infections e.g. boils, abscesses, cellulitis, wound infections.
Dental infections e.g. dentoalveolar abscess.
Bone and joint infections.
*Some members of these species of bacteria produce β-lactamase, rendering them insensitive to amoxicillin alone.
Fleming is also available as Fleming Intravenous for the short term treatment of bacterial infections and for prophylaxis against infection which may be associated with major surgical procedures. Fleming Intravenous is described in a separate Pack Insert.